Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Rectal Diseases 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Kidney Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Diseases 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 43Nivolumab 29atezolizumab 11Specimen Handling 10Cyclophosphamide 10Bevacizumab 10Paclitaxel 9Magnetic Resonance Spectroscopy 9cabozantinib 7Ipilimumab 7Carboplatin 7fludarabine 6durvalumab 6avelumab 6Sunitinib 6Sorafenib 6Oxaliplatin 6Fluorouracil 6Docetaxel 6spartalizumab 5sargramostim 5Leucovorin 5Cisplatin 5Cetuximab 5aldesleukin 4Trastuzumab 4Radiosurgery 4Psychiatric Rehabilitation 4Irinotecan 4Gemcitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × guadecitabine × Gastrointestinal × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡